15 September 2017 - - The plan of Los Angeles, California-based immune-based therapies developer ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) to regain compliance with the NYSE MKT LLC's continued listing standards set forth in Sections 1003(a) (i), 1003(a) and 1003(a) of the NYSE MKT company guide has been accepted, the company said.
The company was previously notified by NYSE MKT that it was not in compliance with the stockholders' equity continued listing standard which requires stockholders' equity of USD6.0 m or more if the company has reported losses from continuing operations and/or net losses in its five most recent fiscal years.
In order to maintain its listing, the company submitted a plan of compliance addressing how it intends to regain compliance and the plan has been accepted by the NYSE MKT.
The company has been granted until December 23, 2018, subject to periodic review by the NYSE MKT for compliance with the initiatives set forth in the plan, to regain compliance.
If the company is not in compliance with the continued listing standards by December 23, 2018, or if it does not make progress consistent with the plan during the plan period, the NYSE MKT staff may initiate delisting proceedings as appropriate.
The NYSE MKT notice has no immediate impact on the listing of the company's common stock, which will continue to trade on the NYSE MKT exchange under the symbol "IMUC," with the added designation of "BC" to indicate that the company is not in compliance with the NYSE MKT's listing standards, subject to periodic review by the NYSE MKT.
ImmunoCellular Therapeutics is a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. 
Its pipeline includes: a Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells; ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent glioblastoma; and ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting ovarian cancer.